Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition

Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Shaheen Kabir, Theodore C. Tarver, III, Veronica Steri, Paul Phojanakong, Juwita Hübner, Carolina E. Morales, Jose M. Rivera, Aaron C. Logan, Benjamin Braun, Elliot Stieglitz, Luke A. Gilbert, Catherine C. Smith

Blood (2024) 144 (Supplement 1): 723.

https://doi.org/10.1182/blood-2024-204168

Published: 2024

Journal Articles

Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML

Jeremy Grenier, Sarah K. Tasian, Elliot Stieglitz, Zied Abdullaev, Gerald Wertheim, Marilyn M. Li, Charles A Phillips

Blood (2024) 144 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2024-203951

Published: 2024

Journal Articles

HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies

Hiroyuki Takamatsu, Emilio Ramos, Bonell Patino-Escobar, Corynn Kasap, Adila Izgutdina, Juwita Werner, Akihito Inagaki, Takeshi Yoroidaka, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, Elliot Stieglitz, Masaki Nagato, Satoshi Tatsuno, Arun P Wiita

Blood (2024) 144 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2024-193709

Published: 2024

Journal Articles

In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia

Matthew Decker, Benjamin J Huang, Tim Ware, Christopher Boone, Michelle Tang, Aishwarya Ballapuram, Julia Ybarra, Katrine Taran, Marcos Amendáriz, Camille Leung, Max Harris, Elliot Stieglitz, Micah Niphakis, Benjamin Cravatt, Kevin Shannon

Blood (2024) 144 (Supplement 1): 5808.

https://doi.org/10.1182/blood-2024-209427

Published: 2024

Journal Articles

Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations

Bogdan Popescu, Madison Piao, Sydney Abelson, Carolina E. Morales, Khadija Yousuf, Jose M. Rivera, Cheryl A C Peretz, Elliot Stieglitz, Catherine C. Smith

Blood (2024) 144 (Supplement 1): 2770.

https://doi.org/10.1182/blood-2024-208386

Published: 2024

Journal Articles

Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia

Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Theodore C. Tarver, III, Shaheen Kabir, Veronica Steri, Juan Antonio Camara Serrano, Fernando Salangsang, Paul Phojanakong, Juwita Hübner, Carolina E. Morales, Jose M. Rivera, Aaron C. Logan, Benjamin Braun, Elliot Stieglitz, Luke A. Gilbert, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2023-180290

Published: 2023

Journal Articles

Risk Stratified Treatment for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase 1/2 Non-Randomized Study of Trametinib and Azacitidine with or without Chemotherapy

Elliot Stieglitz, Yueh-Yun Chi, Bill H. Chang, Sarah K. Tasian, Marielle Yohe, Christopher C Dvorak, Erica Southworth, Janel R. Long-Boyle, Jessica Van Ziffle, Zied Abdullaev, Roy Leong, Alan S. Wayne, Deepa Bhojwani, Mignon L. Loh

Blood (2023) 142 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2023-177838

Published: 2023

Journal Articles

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

Elliot Stieglitz, Alex Lee, Steven P. Angus, Christopher Davis, Donald Barkauskas, David Hall, Scott C. Kogan, Julia Meyer, Steven D. Rhodes, Xiaoling Xuei, Kevin Shannon, Mignon L. Loh, Elizabeth Fox, Brenda J. Weigel

Blood (2023) 142 (Supplement 1): 74.

https://doi.org/10.1182/blood-2023-173153

Published: 2023

Journal Articles

RAS MULTI (ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models

Bogdan Popescu, Elliot Stieglitz, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 2793.

https://doi.org/10.1182/blood-2023-178397

Published: 2023

Journal Articles

Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance

Cheryl A C Peretz, Elaine Tran, Bogdan Popescu, Vanessa E. Kennedy, Tanya Kumar, Lisa McGary, Natalie Tantisira, Eric Wong, Jose M. Rivera, Simayijiang Xirenayi, Elliot Stieglitz, Catherine C. Smith, Juwita Hübner

Blood (2023) 142 (Supplement 1): 4171.

https://doi.org/10.1182/blood-2023-182426

Published: 2023

Journal Articles

LNK/SH2B3 As a Novel Driver in Juvenile Myelomonocytic Leukemia

Astrid Wintering, Anna Hecht, Julia Meyer, Eric Brandon Wong, Deborah L French, Jean Ann Maguire, Chintan Jobaliya, Marta Rojas Vasquez, Sunil J. Desai, Robin Yates Dulman, Eneida R. Nemecek, Farid F Chehab, Mignon L. Loh, Elliot Stieglitz

Blood (2022) 140 (Supplement 1): 6863–6864.

https://doi.org/10.1182/blood-2022-164527

Published: 2022

Journal Articles

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Blood (2022) 140 (Supplement 1): 867–868.

https://doi.org/10.1182/blood-2022-162697

Published: 2022

Journal Articles

Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia

Bogdan Popescu, Carlos Stahlhut, Theodore C. Tarver, III, Timothy T. Ferng, Cheryl Peretz, Sydney Wishner, Paul Phojanakong, Veronica Steri, Eric B. Wong, Jose M. Rivera, Elliot Stieglitz, Catherine C. Smith

Blood (2021) 138 (Supplement 1): 2231.

https://doi.org/10.1182/blood-2021-145964

Published: 2021

Journal Articles

MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521

Elliot Stieglitz, Mignon L. Loh, Julia Meyer, Chujing Zhang, Donald A Barkauskas, David Hall, Elizabeth Fox, Brenda J. Weigel

Blood (2021) 138 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2021-144850

Published: 2021

Journal Articles

Targeting M2-Tumor Associated Macrophages By Arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse

Santhosh Kumar Pasupuleti, Baskar Ramdas, Kai Yang, Chujing Zhang, Elliot Stieglitz, Reuben Kapur

Blood (2021) 138 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2021-153976

Published: 2021

Journal Articles

Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Alyssa L. Kennedy, MDPhD, Kasiani C. Myers, MD, James Bowman, PhD, Christopher J. Gibson, MD, Gwen M. Muscato, Robert Klein, Kaitlyn Ballotti, Nicholas Camarda, Elissa M. Furutani, MD, Chad E. Harris, MS, Shanshan Liu, PhD, Ashley Galvin, Maggie Malsch, MSN, RN, David C. Dale, MD, John M Gansner, MD PhD, Taizo A. Nakano, MD, Alison A. Bertuch, MD, Adrianna Vlachos, MD, Jeff H. Lipton, MD PhD, Paul Castillo, MD, James Connelly, John Edwards, MD, Nobuko Hijiya, MD, Richard Ho, MD, Inga Hofmann, MD, James N Huang, MD, Sioban B. Keel, MD, Adam J. Lamble, MD, Bonnie W Lau, MD PhD, Kelly J. Walkovich, MD, Maxim Norkin, MD, Wendy Stock, MD, Steffen Boettcher, Christian Brendel, PhD, Elliot Stieglitz, MD, Mark D. Fleming, MD DPhil, Stella M. Davies, PhD MBBS, MRCP, Edie A. Weller, Chris Bahl, PhD, Scott L. Carter, PhD, Akiko Shimamura, MD PhD, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137125

Published: 2020

Journal Articles

Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia

Astrid Behnert, MD, Julia Meyer, PhD, Jahan-Yar Parsa, PhD, Aaron Hechmer, PhD, Mignon L. Loh, MD, Adam B. Olshen, PhD, Adam J. de Smith, PhD, Elliot Stieglitz, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143443

Published: 2020

Journal Articles

DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation

Julia Meyer, PhD, Maximillian Schönung, Christian Flotho, MD PhD, Adam B. Olshen, PhD, Mark Hartmann, PhD, Christoph Plass, PhD, Yusuke Okuno, MD PhD, Yoshiyuki Takahashi, MD PhD, Norihiro Murakami, MD PhD, Manabu Wakamatsu, MD, Mignon L. Loh, MD, Charlotte M. Niemeyer, MD, Hideki Muramatsu, MD PhD, Daniel B. Lipka, MD, Elliot Stieglitz, MD

Blood (2019) 134 (Supplement_1): 1693.

https://doi.org/10.1182/blood-2019-131279

Published: 2019

Journal Articles

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Matthew Nix, PhD, Yu-Hsiu T. Lin, BA, Huimin Geng, PhD, Makeba Marcoulis, BA, Paul Phojanakong, BA, Donghui Wang, BA, Veronica Steri, PhD, Jeffrey Whitman, MD, Sagar Bapat, MD PhD, Elliot Stieglitz, MD, Anne Deucher, MD PhD, Kristie L White, MD MD, Byron C Hann, MD PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1337.

https://doi.org/10.1182/blood-2019-130938

Published: 2019

Journal Articles

Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia

Adam J de Smith, PhD, Geneviève Lavoie, PhD, Kyle M Walsh, PhD, Sumeet Aujla, BSc, Erica Evans, BSc, Helen M Hansen, BSc, Ivan Smirnov, PhD, Alice Y Kang, MPH, Martin Zenker, MD, John J Ceremsak, BSc, Elliot Stieglitz, MD, Roberta McKean-Cowdin, PhD, Catherine Metayer, PhD, Philippe P Roux, PhD, Joseph L Wiemels, PhD

Blood (2018) 132 (Supplement 1): 388.

https://doi.org/10.1182/blood-2018-99-119235

Published: 2018

NARROW

CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition

Effective Azacytidine Monotherapy in an Infant with Mosaic NRAS-Driven JMML

HLA-Pan-DP CAR-T Demonstrates Cytotoxicity Against Multiple Hematological Malignancies

In Vivo and In Vitro Chemical Synthetic Lethality of ABHD17 and MEK Inhibition in NRAS -Mutant Acute Myeloid Leukemia

Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations

Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia

Risk Stratified Treatment for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase 1/2 Non-Randomized Study of Trametinib and Azacitidine with or without Chemotherapy

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

RAS MULTI (ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models

Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance

LNK/SH2B3 As a Novel Driver in Juvenile Myelomonocytic Leukemia

Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia

MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521

Targeting M2-Tumor Associated Macrophages By Arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse

Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia

DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only